 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- TAC100-HER2 / Triumvira, Lonza
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. (Poster Bd # M2) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_320;
P1/2
The recommended phase 2 dose was identified as dose level 4 (6-8 x 106 cells/kg). Clinical trial information: NCT04727151.
- TAC100-HER2 / Triumvira, Lonza
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors (Ground Level - Exhibit Hall C - San Diego Convention Center) - Sep 27, 2023 - Abstract #SITC2023SITC_991;
P1/2
Conclusions Treatment with TAC01-HER2 showed manageable safety and promising clinical activity in a heavily pre-treated cancer population. The recommended phase 2 dose was identified as dose level 4 (6
- HER2-TAC ?? T / Triumvira
Preclinical characterization and modelling of allogeneic V?9V?2 TAC T cells for the treatment of solid tumors (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_760;
T cells display strong and specific activity against HER2-expressing tumor models in vitro and in vivo. This highlights the versatility of the TAC platform and its potential in the development of an allogeneic product for therapeutic applications in solid tumors.
- TAC-GUCY2C / Triumvira
Functional characterization of GUCY2C-TAC T cells for the treatment of colorectal cancer using preclinical models (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_711;
Conclusions In vitro and in vivo data confirm strong and specific activity of T cells engineered with humanized GUCY2C-TAC receptors. Taken together, these data support further development of GUCY2C-TAC T cells for therapeutic applications in colorectal cancer.
- TAC01-HER2 (Auto) / Triumvira, Lonza
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_360;
- TAC100-HER2 / Triumvira, Lonza
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3016;
P1/2
Conclusions Treatment with TAC01-HER2 showed manageable safety and promising clinical activity in a heavily pre-treated cancer population. Dose escalation is complete.
- TAC01-HER2 (Auto) / Triumvira, Lonza
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_276;
P1/2
Treatment with the novel T cell therapy, TAC01-HER2 showed manageable safety and promising clinical activity in a heavily pre-treated cancer population, refractory to prior HER2 targeted treatments, including a complete reduction of target lesions in one patient. Dose escalation of TAC01-HER2 is ongoing.
- TAC01-HER2 (Auto) / Triumvira, Lonza
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. (On Demand | S100bc; Poster Bd # 361) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2447;
P1/2
These results in a heavily pre-treated cancer population show manageable safety and promising clinical activity with a novel T cell therapy that may have broad clinical applicability in HER+ cancers. Clinical trial information: NCT04727151.
- TAC01-HER2 (Auto) / Triumvira, Lonza
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors (Section 47; Poster Board #24) - Mar 14, 2023 - Abstract #AACR2023AACR_6050;
P1/2
Dose limiting toxicities (DLTs) are assessed up to 28 days from cell infusion. In Phase II, dose expansion groups will further evaluate the safety, efficacy, and pharmacokinetics of the optimal TAC01-HER2 dose in HER2+ breast and other solid tumor types.
- TAC01-HER2 (Allo) / Triumvira
Preclinical characterization of allogeneic V?9V?2 HER2-TAC T cells for the treatment of HER2-positive solid tumors (Section 22; Poster Board #7) - Mar 14, 2023 - Abstract #AACR2023AACR_3924;
The in vitro and in vivo data confirm strong and specific activity of HER2-targeted TAC ?? T cells against HER2-expressing tumor models and highlights the potential of the TAC platform in the development of an allogeneic product for therapeutic applications in solid tumors.
- TAC01-HER2 (Auto) / Triumvira, Lonza
A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors. (Available On Demand; Poster Board No. P6) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_369;
P1/2
These results in a heavily pre-treated gastrointestinal cancer population show manageable safety and promising efficacy with a novel T cell therapy that may have broad clinical applicability in HER+ cancers. Clinical trial information: NCT04727151.
- TAC01-HER2 (Auto) / Triumvira, Lonza
A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1076;
P1/2
Continued dose escalation of TAC01-HER2 is ongoing. Following completion of each dose level, a Data Safety Monitoring Committee has met to review all AEs to approve or deny escalation to the next highest dose level